A New Frontier for Biotech: Why Hong Kong Is Gaining Ground on Wall Street The conventional wisdom about biotechnology listings has long held that U. S.
markets are the gold standard, offering deeper capital pools and higher valuations than their foreign counterparts. However, a growing trend suggests this narrative is no longer universally true.
Axiom Biosciences' decision to list in Hong Kong before its secondary listing on Wall Street marks a significant shift in the biotech landscape.